- Aims to improve AI capabilities, grow software across industries
- Partnership aims to speed up medicine finding & industry solutions faster
Fire AI Accelerator, a collaborative effort between NVIDIA, Tribe, and Digital Industry Singapore ( DISG) has announced a collaboration with international biotech head Pfizer in Emerging Markets Asia.
In a statement, the Singapore-backed Fire AI Accelerator explained that its goal is to advance AI skills and develop software across industries, driving global business development. The association with Pfizer aims to utilize its extensive community in Southeast Asia, including media, state, universities, accelerators, technical skill, and investors, to expand drug discovery and research processes, bringing innovative treatments to promote more quickly.
The Singapore government has been actively advancing border technologies like AI to support its medical technology and medical ecosystems and improve care quality. In addition to fostering private-public sector partnerships, it has invested over US$ 19 billion ( RM81 billion ) in science and technology research under its Research, Innovation and Enterprise 2025 plan. Through its engagement with DISG, Ignition AI Accelerator aims to attract major international AI companies to Singapore, building a thriving ecosystem for border systems. The throttle also empowers businesses to expand regionally, scaling their companies and accelerating their go-to-market techniques.
The partnership with Pfizer positions Fire AI Accelerator at the vanguard of AI creativity, providing local ecology partners and medical startups with the size and experience of industry giants. Through these collaborations, especially in the healthcare industry, Ignition AI Accelerator is better equipped to drive the development of pioneering therapies, patient treatment, and precision treatments worldwide.
” We are excited to collaborate with Pfizer, one of the leading players in the biopharmaceutical industry,” said Ng Yi Ming, CEO of Tribe. ” Our goal is to empower pharmaceutical giants with the latest advancements in AI to drive innovation in drug discovery and development. This partnership underscores our commitment to accelerating breakthroughs that can significantly impact lives globally. “
Pfizer is at the forefront of leveraging AI to transform drug discovery and development. By integrating into the Ignition AI network, Pfizer aims to create faster, more effective communication with stakeholders, enable a more efficient patient recruitment system, and improve manufacturing yields and cycle times.
” AI is reshaping pharmaceutical research, and our partnership with the Ignition AI Accelerator by Nvidia and Tribe is a significant step towards harnessing these technologies to enhance our communications with patients and healthcare professionals,” said Bei Goh, Regional Client Partner lead, Emerging Asia at Pfizer. ” With access to a thriving startup ecosystem, we are eager to catalyse groundbreaking biomedical startups and accelerate innovations in stakeholder engagement within the industry. “